Personalized Antifibrotic Therapy in CKD Progression

Charlotte Delrue, Michele F Eisenga, Joris R Delanghe, Marijn M Speeckaert, Matthew B Lanktree · 2024

Read Personalized Antifibrotic Therapy in CKD Progression by Charlotte Delrue, Michele F Eisenga, Joris R Delanghe, Marijn M Speeckaert, Matthew B Lanktree (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11678888.txt.

Description

Charlotte Delrue and co-authors review the push toward personal antifibrotic therapy for kidney disease, in a 2024 paper. Chronic kidney disease advances through fibrosis, scar tissue that slowly strangles the organ. Many pathways drive it, from growth factor signals to inflammation routes. Today's drugs, chiefly blockers of the renin-angiotensin system, slow the disease but neither stop nor reverse the scarring. The review argues that one-size treatment has hit its limit.

Precision medicine offers a way forward by sorting patients with protein, metabolite, and gene data. A urine protein signature called CKD273 and gene markers such as APOL1 already help divide patients into groups. Two recently developed antifibrotic drugs are discussed as early examples of the tailored approach.

Catalog record

CREATORCharlotte Delrue, Michele F Eisenga, Joris R Delanghe, Marijn M Speeckaert, Matthew B Lanktree
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11678888

Browse the full library · About the Tower of Babel